Hospital-Acquired Infections Market Size, Share, Growth Analysis, By Type(Equipment (Sterilization Equipment, Disinfection Equipment), Consumables (Disinfectants, Sterilization Consumables), By Treatment(Antibacterial, Antiviral, Antifungal, Others), By Infection Type(Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection), By End User(Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region - Industry Forecast 2024-2031

Global Hospital-Acquired Infections Market size was valued at USD 29.1 billion in 2019 and is poised to grow from USD 29.54 billion in 2023 to USD 33.77 billion by 2031, growing at a CAGR of 1.5% in the forecast period (2024-2031).

The market for hospital acquired infection control is highly competitive. Market participants are launching strategic activities such as customer acquisition, strategic collaborations, distribution network strengthening, and R&D. Key firms are also diversifying their portfolios and investing in new technologies to boost their market share. Steris, for example, expanded its offerings by acquiring Cantel Medical, a significant producer of infection prevention products and services, in June 2021. '3M Company', 'Abbott Laboratories', 'Advanced Sterilization Products Services Inc. (ASP)', 'Becton, Dickinson and Company (BD)', 'Belimed AG', 'BioMérieux SA', 'Cantel Medical Corp.', 'Getinge Group', 'Johnson & Johnson', 'Merck & Co., Inc.', 'Pfizer Inc.', 'Roche Diagnostics Corporation', 'Stryker Corporation', 'Thermo Fisher Scientific Inc.', 'Steris Corporation', 'Zimmer Biomet Holdings, Inc.', 'Ansell Limited', 'Molnlycke Health Care AB', 'Cantel Medical Corp.'

Rising number of surgical procedures is likely to drive market growth

The rise in the prevalence of chronic diseases such as gastroesophageal reflux disease (GERD), IBD, peptic ulcer disease, crohn's disease, diabetes, hypertension, cardiovascular disorders, cancer, and others due to environmental pollution, smoking, unhealthy lifestyles, poor nutrition and diet, and high intake of carcinogenic substances will drive the market for hospital acquired infection control devices. According to the International Diabetes Federation's Diabetes Atlas 10th edition report 2021, 537 million individuals (20-79 years) worldwide are diabetic. This figure is expected to climb to 643 million by 2030 and 783 million by 2045. The increased frequency of chronic disease will increase the number of surgical procedures. As the number of procedures increases, so will the risk of hospital-acquired infections. Infection transmission can be stopped by using adequate sterilization and disinfection procedures. As a result of the increased incidence of chronic illnesses, the rising number of surgical operations may raise the prevalence of hospital acquired infections, thus boosting the demand for hospital acquired infection control products. Thus, the aforementioned aspect is expected to boost the overall market growth of hospital acquired infection control products over the forecast period.

North America dominated the market in 2021, accounting for more than 34.0% of total sales. The substantial share can be due to the presence of key players, activities implemented by them in the public and commercial sectors, and increased awareness of HAIs in this region. For example, in December 2020, Ecolab, headquartered in the United States, acquired vanBaerle Hygiene AG in Switzerland. This expanded Ecolab's product line and service capabilities to include a comprehensive spectrum of cleaning, disinfection, and hygiene solutions.